Back to Stocks

ATOS

ATOSSA THERAPEUTICS, INC.
8 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Atossa Therapeutics is transitioning from a period of defensive litigation to a phase of clinical execution.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

The financial reality facing Atossa Therapeutics is precarious, characterized by a rapid cash drain and a stark 'going concern' warning from management.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every ATOS filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The latest 10-Q paints a picture of a company at a binary inflection point. On one side, Atossa has cleared a major legal hurdle and is seeing early clinical signals that suggest (Z)-endoxifen could be a potent alternative to standard endocrine therapies. The strategic pivot toward rare diseases and the pursuit of PRVs offers a sophisticated path to value creation that transcends simple drug approval. However, these clinical prospects are countered by a fragile balance sheet. The company is effectively racing against its own burn rate to reach the H2 2026 data readouts. Investors must weigh the high-conviction clinical data and IP security against the very real possibility of further dilution or a liquidity crisis. The outcome of the remaining PTAB proceedings and the company's ability to utilize its ATM facility without crushing existing shareholders will be the deciding factors in whether Atossa survives to realize its clinical potential.

Selected Quarter

Core Takeaway

Atossa has neutralized its primary legal threat, but now faces a race against time to secure funding before its cash reserves vanish.

Investor Lens

The trade-off is between the high-reward potential of H2 2026 clinical readouts and the high probability of significant shareholder dilution.

Watch Next

Top-line durability data from the Karisma study and final PTAB decisions on Endoxifen patents expected by November 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.20Q1 '26 (10-K)-0.12Q2 '26 (10-Q)

Signal Timeline

28 of 32
Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 8

Net loss widened to $9.6 million in Q1 2026 compared to $6.7 million in Q1 2025.

earnings miss
70%
bearishMay 8

G&A expenses surged 56% due to high legal fees and administrative costs.

margin compression
60%
neutralMay 8

Established a new $50 million ATM facility to combat dwindling cash reserves.

capital raise
50%
bullishMay 8

Received FDA Rare Pediatric Disease and Orphan Drug designations for DMD and MAS.

regulatory action
80%
bearishMay 8

Net loss widened to $9.6 million in Q1 2026 compared to $6.7 million in Q1 2025.

earnings miss
70%
bearishMay 8

G&A expenses surged 56% due to high legal fees and administrative costs.

margin compression
60%
neutralMay 8

Established a new $50 million ATM facility to combat dwindling cash reserves.

capital raise
50%
bullishMay 8

Received FDA Rare Pediatric Disease and Orphan Drug designations for DMD and MAS.

regulatory action
80%
bearishMay 8

Net loss widened to $9.6 million in Q1 2026 compared to $6.7 million in Q1 2025.

earnings miss
70%
bearishMay 8

G&A expenses surged 56% due to high legal fees and administrative costs.

margin compression
60%
neutralMay 8

Established a new $50 million ATM facility to combat dwindling cash reserves.

capital raise
50%
bullishMay 8

Received FDA Rare Pediatric Disease and Orphan Drug designations for DMD and MAS.

regulatory action
80%
bearishMay 8

Net loss widened to $9.6 million in Q1 2026 compared to $6.7 million in Q1 2025.

earnings miss
70%
bearishMay 8

G&A expenses surged 56% due to high legal fees and administrative costs.

margin compression
60%
neutralMay 8

Established a new $50 million ATM facility to combat dwindling cash reserves.

capital raise
50%
bullishMay 8

Received FDA Rare Pediatric Disease and Orphan Drug designations for DMD and MAS.

regulatory action
80%
bearishMay 8

Net loss widened to $9.6 million in Q1 2026 compared to $6.7 million in Q1 2025.

earnings miss
70%
bearishMay 8

G&A expenses surged 56% due to high legal fees and administrative costs.

margin compression
60%
neutralMay 8

Established a new $50 million ATM facility to combat dwindling cash reserves.

capital raise
50%
bullishMay 8

Received FDA Rare Pediatric Disease and Orphan Drug designations for DMD and MAS.

regulatory action
80%
bearishMay 8

Net loss widened to $9.6 million in Q1 2026 compared to $6.7 million in Q1 2025.

earnings miss
70%
bearishMay 8

G&A expenses surged 56% due to high legal fees and administrative costs.

margin compression
60%
neutralMay 8

Established a new $50 million ATM facility to combat dwindling cash reserves.

capital raise
50%
bullishMay 8

Received FDA Rare Pediatric Disease and Orphan Drug designations for DMD and MAS.

regulatory action
80%
bearishMay 8

Net loss widened to $9.6 million in Q1 2026 compared to $6.7 million in Q1 2025.

earnings miss
70%
bearishMay 8

G&A expenses surged 56% due to high legal fees and administrative costs.

margin compression
60%
neutralMay 8

Established a new $50 million ATM facility to combat dwindling cash reserves.

capital raise
50%
bullishMay 8

Received FDA Rare Pediatric Disease and Orphan Drug designations for DMD and MAS.

regulatory action
80%

Filing History

10-QMay 8, 2026
Expand Sequence

The latest 10-Q paints a picture of a company at a binary inflection point. On one side, Atossa has cleared a major legal hurdle and is seeing early clinical signals that suggest (Z)-endoxifen could be a potent alternative to standard endocrine therapies. The strategic pivot toward rare diseases and the pursuit of PRVs offers a sophisticated path to value creation that transcends simple drug approval. However, these clinical prospects are countered by a fragile balance sheet. The company is effectively racing against its own burn rate to reach the H2 2026 data readouts. Investors must weigh the high-conviction clinical data and IP security against the very real possibility of further dilution or a liquidity crisis. The outcome of the remaining PTAB proceedings and the company's ability to utilize its ATM facility without crushing existing shareholders will be the deciding factors in whether Atossa survives to realize its clinical potential.

10-KMar 25, 2026
Expand Sequence

The 10-K filing reveals a company at a critical inflection point, balancing high-potential clinical data against a fragile balance sheet. The transition to a multi-indication platform involving DMD and MAS is an ambitious move to diversify risk, but it simultaneously increases the capital requirements for a firm already struggling with a 'going concern' warning. The 2026 data calendar for the Karisma and EVANGELINE studies will be the ultimate arbiter of the company's value. Investors are essentially betting on a binary outcome: either the upcoming clinical readouts provide enough validation to secure a major partnership or a high-valuation capital raise, or the company will succumb to its burn rate and patent litigation. The successful execution of the reverse stock split to maintain Nasdaq compliance suggests a management team fighting for survival, but the fundamental risk remains the gap between current cash reserves and the cost of reaching an NDA filing.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.